Developer docs
API playgroundTry for free, no card

Search company profiles

Neurosterix

Full company profile

uuid0000lt7

Namestring
Neurosterix
Legal namestring
Neurosterix Pharma Sàrl
Websiteurl
neurosterix.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Neurosterix is a clinical-stage biopharmaceutical company developing first- and best-in-class allosteric modulators for neuropsychiatric disorders, including schizophrenia, mood disorders, and anxiety disorders. Founded in April 2024 as a spin-out from Addex Therapeutics, the company is headquartered in Geneva, Switzerland with a US office in Boston, Massachusetts. Its lead program NTX-253, an oral positive allosteric modulator (PAM) of the muscarinic M4 receptor, is currently in Phase 1 clinical development for schizophrenia with results expected in July 2026. A second M4 PAM, NTX-529, is in IND-enabling studies for psychosis and mood-related disorders, while NTX-819 — a first-in-class negative allosteric modulator (NAM) of the metabotropic glutamate receptor 7 (mGlu7) — is in preclinical development for mood and anxiety disorders.

The company's therapeutic approach is grounded in a proprietary allosteric modulator discovery platform that includes an 80,000+ knowledge-enriched compound library and 200+ CNS functional assays, supported by nearly 20 high-throughput screening campaigns across muscarinic and glutamatergic receptor families. Allosteric modulators are designed to act as "dimmer switches" rather than on/off toggles, binding outside the orthosteric site to enable tunable receptor engagement with the goal of improved selectivity and tolerability versus conventional neuropsychiatric drugs. The platform is backed by 100+ patents and 30+ peer-reviewed publications. Neurosterix is led by CEO and Co-Founder Fred Callori (also Managing Director at lead investor Perceptive Advisors), CSO Robert Lütjens (ex-Addex, 20+ years in CNS drug discovery), CMO Doug Feltner (ex-AbbVie VP, ex-Pfizer VP), and COO Ted Keysor (ex-Cerevel, ex-Biogen), among others.

The business model is currently pre-commercial. Neurosterix raised a $63 million Series A in April 2024 led by Perceptive Xontogeny Venture Fund II with participation from Acorn Bioventures; Addex Therapeutics retained a 20% equity stake in exchange for the contributed platform and assets. Future revenue is expected to come from (i) prescription pharmaceutical product sales through traditional biopharmaceutical distribution channels once NTX-253 or other candidates receive regulatory approval, and (ii) potential licensing and royalty arrangements based on the allosteric modulator platform, analogous to Addex's prior collaborations with Janssen, Merck, and Indivior. End customers — patients with schizophrenia, mood, and anxiety disorders — are not yet being served commercially, and pricing has not been established.

Short descriptiontext

Neurosterix is a clinical-stage biopharmaceutical company developing first- and best-in-class allosteric modulators for neuropsychiatric disorders including schizophrenia, mood, and anxiety disorders. Its pipeline includes NTX-253 (Phase 1 M4 PAM for schizophrenia), NTX-529 (IND-enabling), and NTX-819 (preclinical mGlu7 NAM), powered by a proprietary discovery platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGeneva, Switzerland
HQ citystring
Geneva
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allosteric modulators, CNS drug discovery, neurological therapeutics, muscarinic receptor modulators, neuropsychiatric drug development
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Biopharmaceutical Drug Development
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Once clinical development is complete and regulatory approvals are obtained, Neurosterix will generate revenue through the sale of prescription pharmaceutical products for neuropsychiatric disorders. The company is currently in preclinical and Phase 1 stages with lead program NTX-253 for schizophrenia.

startupticker.ch
2Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Potential future revenue from licensing proprietary allosteric modulator technology and platform capabilities to pharmaceutical partners, as demonstrated by Addex Therapeutics' prior collaborations with Janssen, Merck, and Indivior.

startupticker.ch
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neurosterix develops first- and best-in-class allosteric modulator drug candidates for neuropsychiatric disorders, including schizophrenia, mood, and anxiety disorders. The company's pipeline includes NTX-253 (M4 PAM, Phase 1 for schizophrenia), NTX-529 (M4 PAM, IND-enabling for psychosis/mood disorders), and NTX-819 (mGlu7 NAM, preclinical for mood/anxiety). These programs are powered by a proprietary discovery platform featuring 200+ functional CNS assays and an 80,000+ compound library.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 study completion expected July 2026 for lead program NTX-253
+2 more records
Product overview1 text field

Neurosterix is developing a focused pipeline of first- and best-in-class allosteric modulator therapeutics for neuropsychiatric disorders. The core offering includes three named drug candidates: NTX-253 (Phase 1, M4 PAM for schizophrenia), NTX-529 (IND-enabling, M4 PAM for psychosis/mood disorders), and NTX-819 (preclinical, mGlu7 NAM for mood disorders). These programs are powered by the company's proprietary allosteric modulator discovery platform featuring an 80,000+ compound library and 200+ CNS functional assays. The company's approach uses allosteric modulators that act like dimmer switches to fine-tune receptor activity rather than simply turning signaling on or off.

Product and service4 records
1NTX-253
CategoryDrug Candidate
Description

A potent, selective, oral positive allosteric modulator (PAM) of the M4 muscarinic receptor for treating schizophrenia. NTX-253 fine-tunes muscarinic signaling to reduce psychosis symptoms while avoiding movement disorders and metabolic complications associated with traditional dopamine antagonists. Currently in Phase 1 clinical trials.

2NTX-529
CategoryDrug Candidate
Description

A best-in-class M4 positive allosteric modulator (PAM) for psychosis and mood-related disorders. Currently in IND-enabling phase.

3NTX-819
CategoryDrug Candidate
Description

A first-in-class, oral negative allosteric modulator (NAM) of the metabotropic glutamate receptor 7 (mGlu7) for mood and anxiety disorders. Modulates glutamatergic signaling to restore balance in brain circuits implicated in stress, agitation, and anhedonia. Currently in preclinical development.

4Allosteric Modulator Discovery Platform
CategoryDiscovery Platform
Description

Proprietary discovery engine enabling highly selective, tunable engagement of CNS targets through 80,000+ compound library, 200+ functional CNS assays, and nearly 20 successful high-throughput screening campaigns across muscarinic, glutamatergic, and other receptor families. Supports development of first- and best-in-class allosteric modulators.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-03
Description

Neurosterix acquired a portfolio of preclinical assets and the allosteric modulator drug discovery platform from Addex Therapeutics. Addex retained a 20% equity stake in Neurosterix and continues its partnerships in the neurological field. Addex leadership (Tim Dyer) co-founded Neurosterix and served as CEO/CFO until May 2025.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developed xanomeline-trospium (Cobenfy) for schizophrenia via muscarinic receptor targeting, directly competing with Neurosterix's M4 PAM approach. Acquired by Bristol Myers Squibb for $14 billion in 2024.

TypeDirect peer
Description

CNS-focused biopharmaceutical company developing therapies for schizophrenia, Parkinson's, and epilepsy. Acquired by AbbVie for $8.7 billion in 2024; shares Neurosterix's neuroscience pipeline focus and similar leadership backgrounds.

TypeDirect peer
Description

CNS-focused company developing Zurzuvae (zuranolone) for postpartum depression and other neuropsychiatric conditions. Comparable in CNS therapeutic area focus and clinical-stage development profile.

TypeDirect peer
Description

Clinical-stage neuroscience company developing precision medicines for brain disorders, including schizophrenia and depression. Similar focus on novel CNS mechanisms and clinical development stage.

TypeEmerging player
Description

Clinical-stage CNS company developing therapies for schizophrenia and other psychiatric disorders. Comparable in indication focus and emerging clinical-stage profile targeting muscarinic and other CNS mechanisms.

TypeBroad incumbent
Description

Commercial-stage CNS company with approved products Auvelity (depression) and Sunosi. Comparable in CNS therapeutic focus with broader pipeline spanning depression, migraine, and narcolepsy.

TypeBroad incumbent
Description

Established CNS biopharmaceutical company with approved products including Lybalvi (schizophrenia) and Aristada. Lisa Corey, Neurosterix's VP of Clinical Operations, previously led global trial execution at Alkermes.

8Boehringer Ingelheim (CNS pipeline)
TypeBroad incumbent
Description

Major pharmaceutical company with active CNS pipeline including schizophrenia and depression programs. Represents potential partnership or acquisition counterparty given CNS focus and capital capacity.

9Sumitomo Pharma (formerly Sumitomo Dainippon)
TypeBroad incumbent
Description

Global pharmaceutical company with significant CNS franchise including Latuda (lurasidone) for schizophrenia. Comparable in CNS therapeutic focus with commercial schizophrenia asset.

TypeOthers
Description

Bristol Myers Squibb acquired Karuna and now markets Cobenfy in schizophrenia, representing the most direct competitive threat to Neurosterix's M4 PAM program in the muscarinic mechanism space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurosterix

Biopharmaceutical Drug Developmentneurosterix.com

Neurosterix is a clinical-stage biopharmaceutical company developing first- and best-in-class allosteric modulators for neuropsychiatric disorders including schizophrenia, mood, and anxiety disorders. Its pipeline includes NTX-253 (Phase 1 M4 PAM for schizophrenia), NTX-529 (IND-enabling), and NTX-819 (preclinical mGlu7 NAM), powered by a proprietary discovery platform.

What Neurosterix does

Neurosterix is a clinical-stage biopharmaceutical company developing first- and best-in-class allosteric modulators for neuropsychiatric disorders, including schizophrenia, mood disorders, and anxiety disorders. Founded in April 2024 as a spin-out from Addex Therapeutics, the company is headquartered in Geneva, Switzerland with a US office in Boston, Massachusetts. Its lead program NTX-253, an oral positive allosteric modulator (PAM) of the muscarinic M4 receptor, is currently in Phase 1 clinical development for schizophrenia with results expected in July 2026. A second M4 PAM, NTX-529, is in IND-enabling studies for psychosis and mood-related disorders, while NTX-819 — a first-in-class negative allosteric modulator (NAM) of the metabotropic glutamate receptor 7 (mGlu7) — is in preclinical development for mood and anxiety disorders.

The company's therapeutic approach is grounded in a proprietary allosteric modulator discovery platform that includes an 80,000+ knowledge-enriched compound library and 200+ CNS functional assays, supported by nearly 20 high-throughput screening campaigns across muscarinic and glutamatergic receptor families. Allosteric modulators are designed to act as "dimmer switches" rather than on/off toggles, binding outside the orthosteric site to enable tunable receptor engagement with the goal of improved selectivity and tolerability versus conventional neuropsychiatric drugs. The platform is backed by 100+ patents and 30+ peer-reviewed publications. Neurosterix is led by CEO and Co-Founder Fred Callori (also Managing Director at lead investor Perceptive Advisors), CSO Robert Lütjens (ex-Addex, 20+ years in CNS drug discovery), CMO Doug Feltner (ex-AbbVie VP, ex-Pfizer VP), and COO Ted Keysor (ex-Cerevel, ex-Biogen), among others.

The business model is currently pre-commercial. Neurosterix raised a $63 million Series A in April 2024 led by Perceptive Xontogeny Venture Fund II with participation from Acorn Bioventures; Addex Therapeutics retained a 20% equity stake in exchange for the contributed platform and assets. Future revenue is expected to come from (i) prescription pharmaceutical product sales through traditional biopharmaceutical distribution channels once NTX-253 or other candidates receive regulatory approval, and (ii) potential licensing and royalty arrangements based on the allosteric modulator platform, analogous to Addex's prior collaborations with Janssen, Merck, and Indivior. End customers — patients with schizophrenia, mood, and anxiety disorders — are not yet being served commercially, and pricing has not been established.

Neurosterix firmographics

Firmographics
Name
Neurosterix
Legal name
Neurosterix Pharma Sàrl
Website
https://neurosterix.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Neurosterix is a clinical-stage biopharmaceutical company developing first- and best-in-class allosteric modulators for neuropsychiatric disorders including schizophrenia, mood, and anxiety disorders. Its pipeline includes NTX-253 (Phase 1 M4 PAM for schizophrenia), NTX-529 (IND-enabling), and NTX-819 (preclinical mGlu7 NAM), powered by a proprietary discovery platform.
Ownership category
akta.pro rank

Neurosterix industry classification

Industry
Product category
Biopharmaceutical Drug Development
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Allosteric modulators
  • CNS drug discovery
  • Neurological therapeutics
  • Muscarinic receptor modulators
  • Neuropsychiatric drug development

Where Neurosterix is headquartered

Location

Headquarters

HQ city
Geneva
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Neurosterix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Once clinical development is complete and regulatory approvals are obtained, Neurosterix will generate revenue through the sale of prescription pharmaceutical products for neuropsychiatric disorders. The company is currently in preclinical and Phase 1 stages with lead program NTX-253 for schizophrenia.
  2. Licensing and Partnership Revenue: Potential future revenue from licensing proprietary allosteric modulator technology and platform capabilities to pharmaceutical partners, as demonstrated by Addex Therapeutics' prior collaborations with Janssen, Merck, and Indivior.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Neurosterix product offering

Product offering

Core offering

Neurosterix develops first- and best-in-class allosteric modulator drug candidates for neuropsychiatric disorders, including schizophrenia, mood, and anxiety disorders. The company's pipeline includes NTX-253 (M4 PAM, Phase 1 for schizophrenia), NTX-529 (M4 PAM, IND-enabling for psychosis/mood disorders), and NTX-819 (mGlu7 NAM, preclinical for mood/anxiety). These programs are powered by a proprietary discovery platform featuring 200+ functional CNS assays and an 80,000+ compound library.

Product overview

Neurosterix is developing a focused pipeline of first- and best-in-class allosteric modulator therapeutics for neuropsychiatric disorders. The core offering includes three named drug candidates: NTX-253 (Phase 1, M4 PAM for schizophrenia), NTX-529 (IND-enabling, M4 PAM for psychosis/mood disorders), and NTX-819 (preclinical, mGlu7 NAM for mood disorders). These programs are powered by the company's proprietary allosteric modulator discovery platform featuring an 80,000+ compound library and 200+ CNS functional assays. The company's approach uses allosteric modulators that act like dimmer switches to fine-tune receptor activity rather than simply turning signaling on or off.

Differentiator

Problem solved

Functional benefit

Products and services

  • NTX-253 A potent, selective, oral positive allosteric modulator (PAM) of the M4 muscarinic receptor for treating schizophrenia. NTX-253 fine-tunes muscarinic signaling to reduce psychosis symptoms while avoiding movement disorders and metabolic complications associated with traditional dopamine antagonists. Currently in Phase 1 clinical trials.
  • NTX-529 A best-in-class M4 positive allosteric modulator (PAM) for psychosis and mood-related disorders. Currently in IND-enabling phase.
  • NTX-819 A first-in-class, oral negative allosteric modulator (NAM) of the metabotropic glutamate receptor 7 (mGlu7) for mood and anxiety disorders. Modulates glutamatergic signaling to restore balance in brain circuits implicated in stress, agitation, and anhedonia. Currently in preclinical development.
  • Allosteric Modulator Discovery Platform Proprietary discovery engine enabling highly selective, tunable engagement of CNS targets through 80,000+ compound library, 200+ functional CNS assays, and nearly 20 successful high-throughput screening campaigns across muscarinic, glutamatergic, and other receptor families. Supports development of first- and best-in-class allosteric modulators.

Quantifiable outcome

  • Phase 1 study completion expected July 2026 for lead program NTX-253
  • +2 more outcomes

Companies that use Neurosterix

Customer profile

Segments3 records

Ideal customer profiles3 records

Neurosterix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Neurosterix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Addex TherapeuticscoreStrategic or Co-development Partner · 3 April 2024Neurosterix acquired a portfolio of preclinical assets and the allosteric modulator drug discovery platform from Addex Therapeutics. Addex retained a 20% equity stake in Neurosterix and continues its partnerships in the neurological field. Addex leadership (Tim Dyer) co-founded Neurosterix and served as CEO/CFO until May 2025.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Neurosterix competitors and assessment

Company assessment

Direct peers

  • Karuna Therapeutics: Developed xanomeline-trospium (Cobenfy) for schizophrenia via muscarinic receptor targeting, directly competing with Neurosterix's M4 PAM approach. Acquired by Bristol Myers Squibb for $14 billion in 2024.
  • Cerevel Therapeutics: CNS-focused biopharmaceutical company developing therapies for schizophrenia, Parkinson's, and epilepsy. Acquired by AbbVie for $8.7 billion in 2024; shares Neurosterix's neuroscience pipeline focus and similar leadership backgrounds.
  • Sage Therapeutics: CNS-focused company developing Zurzuvae (zuranolone) for postpartum depression and other neuropsychiatric conditions. Comparable in CNS therapeutic area focus and clinical-stage development profile.
  • Neumora Therapeutics: Clinical-stage neuroscience company developing precision medicines for brain disorders, including schizophrenia and depression. Similar focus on novel CNS mechanisms and clinical development stage.

Emerging players

  • MapLight Therapeutics: Clinical-stage CNS company developing therapies for schizophrenia and other psychiatric disorders. Comparable in indication focus and emerging clinical-stage profile targeting muscarinic and other CNS mechanisms.

Broad incumbents

  • Axsome Therapeutics: Commercial-stage CNS company with approved products Auvelity (depression) and Sunosi. Comparable in CNS therapeutic focus with broader pipeline spanning depression, migraine, and narcolepsy.
  • Alkermes: Established CNS biopharmaceutical company with approved products including Lybalvi (schizophrenia) and Aristada. Lisa Corey, Neurosterix's VP of Clinical Operations, previously led global trial execution at Alkermes.
  • Boehringer Ingelheim (CNS pipeline): Major pharmaceutical company with active CNS pipeline including schizophrenia and depression programs. Represents potential partnership or acquisition counterparty given CNS focus and capital capacity.
  • Sumitomo Pharma (formerly Sumitomo Dainippon): Global pharmaceutical company with significant CNS franchise including Latuda (lurasidone) for schizophrenia. Comparable in CNS therapeutic focus with commercial schizophrenia asset.

Others

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Neurosterix social profiles

Digital presence

Neurosterix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurosterix leadership team

Management profile

Number of profiles

Profiles1 record

Neurosterix funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurosterix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurosterix

What does Neurosterix do?

Neurosterix develops first- and best-in-class allosteric modulator drug candidates for neuropsychiatric disorders, including schizophrenia, mood, and anxiety disorders. The company's pipeline includes NTX-253 (M4 PAM, Phase 1 for schizophrenia), NTX-529 (M4 PAM, IND-enabling for psychosis/mood disorders), and NTX-819 (mGlu7 NAM, preclinical for mood/anxiety). These programs are powered by a proprietary discovery platform featuring 200+ functional CNS assays and an 80,000+ compound library.

Is Neurosterix a public or private company?

Neurosterix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neurosterix founded?

Neurosterix was founded in 2024. It employs 11 to 50 people.

Where is Neurosterix based?

Neurosterix is headquartered in Geneva, Switzerland, in the Europe region.

How does Neurosterix make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Revenue.

Who are Neurosterix's main competitors?

Direct peers on record are Karuna Therapeutics, Cerevel Therapeutics, Sage Therapeutics and Neumora Therapeutics. MapLight Therapeutics is listed as an emerging player. Broad incumbents are Axsome Therapeutics, Alkermes, Boehringer Ingelheim (CNS pipeline) and Sumitomo Pharma (formerly Sumitomo Dainippon). Karuna Therapeutics (historical) / BMS Cobenfy franchise is listed as an others.

Does Neurosterix have an API?

No public API is recorded for Neurosterix.

What industry is Neurosterix in?

Neurosterix's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyNeurosterix pockets $105m to advance neuropsychiatry pipeline - Pharmaceutical TechnologyNeurosterix raised $105M in a Series B led by RTW Investments to advance its neuropsychiatric pipeline. The lead asset NTX-253, a selective M4 modulator for schizophrenia, will move to Phase II after Phase I success. The company also plans to progress two earlier-stage candidates and bolster its leadership team.FinanzNachrichten.deNeurosterix gibt eine Serie-B-Finanzierung in Höhe von 105 Millionen US-DollarNeurosterix, a biotech firm developing neuropsychiatric modulators, closed a $105 million Series B financing round led by RTW Investments. New investors include Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors, and Dellora.citybizNeurosterix Raises $105M Series B to Advance Schizophrenia DrugNeurosterix raised $105 million in Series B funding led by RTW Investments to advance its schizophrenia drug NTX-253 into Phase 2 clinical development. The funds will support the lead program, with Phase 1 data showing a pharmacokinetic profile for once-daily dosing. The company also has other programs in development.FinSMEsNeurosterix Raises $105M in Series B FundingNeurosterix raised $105M in Series B funding led by RTW Investments. The company will use the funds to advance its lead program NTX-253 into Phase 2 clinical development for schizophrenia and support its pipeline of selective allosteric modulators.LelezardNeurosterix annonce un financement de série B de 105 millions d'USD et la nomination de dirigeants de premier plan spécialisés dans le développement de médicaments neuropsychiatriquesNeurosterix announced a $105 million Series B funding round led by RTW Investments, with participation from Janus Henderson, GV, and others. The funds will advance its Phase 2 clinical trials for NTX-253, a selective M4 modulator for schizophrenia. The company also appointed Andrew Miller as CEO and other executives.Pulse 2.0Neurosterix: $105 Million Series B To Advance Schizophrenia Drug Into Phase 2Neurosterix raised $105 million in Series B financing led by RTW Investments to advance its schizophrenia drug NTX-253 into Phase 2. The company also expanded its pipeline of selective allosteric modulators for neuropsychiatric disorders. The funding supports further clinical evaluation of NTX-253 and other candidates.BioSpaceNeurosterix nabs $105M, recruits Karuna veterans for schizophrenia pushNeurosterix raised $105 million to advance its schizophrenia candidate NTX-253 into mid-stage trials, appointing three former Karuna Therapeutics leaders. The funding, led by RTW Investments, follows its $63 million series A and adds Addex's 8.5% stake. The company plans Phase 2 trials for the M4 PAM.Startup ResearcherNeurosterix Raises $105 Million Series B for Schizophrenia DrugNeurosterix raised $105 million in a Series B round led by RTW Investments. The biotech will use the funds to advance NTX-253, a schizophrenia drug, into Phase 2 testing after completing Phase 1 studies. The company also announced three leadership appointments.startupticker.ch$105 Million to transform neuropsychiatric care by fine-tuning brain signalingNeurosterix closed a $105 million Series B led by RTW Investments to advance NTX-253 into Phase 2 clinical development for schizophrenia. The company's lead program, a selective M4 PAM, completed Phase 1 studies with supportive pharmacokinetic data. Proceeds will also support its broader pipeline of allosteric modulators.Business Wire BlogNeurosterix Announces $105 Million Series B Financing and Appointments of Leading Neuropsychiatry Drug Development ExecutivesNeurosterix closed a $105 million Series B financing led by RTW Investments to advance its lead program NTX-253 into Phase 2 clinical development for schizophrenia. The company also appointed Andrew Miller as Executive Chair and added Edmund Harrigan and Stephen Brannan to the board and advisory board.